Immucell Corp (ICCC)

$8.00 +0.18 (2.30%)
Market Cap 70.75M
Revenue (ttm) 27.64M
Net Income (ttm) -1.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.76%
Debt to Equity Ratio 0.34
Volume 9,500
Avg Vol 17,540
Day's Range N/A - N/A
Shares Out 9.05M
Stochastic %K 81%
Beta 0.30
Analysts Strong Buy
Price Target $14.00

Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus...

Industry: Biotechnology
Sector: Healthcare
Phone: 207 878 2770
Address:
56 Evergreen Drive, Portland, United States
theRooster007
theRooster007 Apr. 22 at 4:49 PM
$ICCC https://www.zacks.com/stock/news/2905060/the-zacks-analyst-blog-the-goldman-sachs-nextera-shopify-landmark-and-immucell
0 · Reply
theRooster007
theRooster007 Apr. 20 at 9:47 PM
$ICCC both on newest ceo and newest board member of the strategy and tech committee dr. Gilles guilmette resumes.....🤔
0 · Reply
theRooster007
theRooster007 Apr. 20 at 1:56 PM
$ICCC blue skies at $11
1 · Reply
theRooster007
theRooster007 Apr. 16 at 3:24 PM
$ICCC pe firm archimeds largest global animal health company Ceva can do manufacturing. Current ceo and newest leader of strategy committee linked to archimed.
0 · Reply
TommyTwenty
TommyTwenty Apr. 16 at 2:42 AM
$ICCC
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 6:08 PM
$ICCC RSI: 75.00, MACD: 0.2625 Vol: 0.48, MA20: 6.62, MA50: 6.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
focafoca99
focafoca99 Apr. 14 at 7:37 PM
$ICCC disclosed a board refresh with three directors stepping off and two new directors joining effective April 15.
0 · Reply
TommyTwenty
TommyTwenty Apr. 14 at 6:04 PM
$ICCC 1 new executive that comes from the same private equity firm as the new ceo. 1 new executive with a history of animal health M&A. They’re reducing the board to 7 after just reporting 28% sales increase. 6 independent directors and the ceo. The pop today on volume feels like buyout speculation.
0 · Reply
focafoca99
focafoca99 Apr. 13 at 10:01 PM
$ICCC added Gilles Guillemette and Anthony DiMarco to the board, reduced the board to seven seats and created a new Strategy and Technology Committee.
0 · Reply
theRooster007
theRooster007 Apr. 13 at 8:52 PM
$ICCC https://www.stocktitan.net/news/ICCC/immu-cell-bolsters-its-innovation-strategy-with-appointments-of-dr-6ru4bnelyvav.html
1 · Reply
Latest News on ICCC
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

Apr 13, 2026, 4:38 PM EDT - 10 days ago

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

Apr 8, 2026, 4:05 PM EDT - 15 days ago

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

Mar 18, 2026, 4:05 PM EDT - 5 weeks ago

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

Mar 4, 2026, 4:05 PM EST - 7 weeks ago

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

Feb 18, 2026, 8:37 AM EST - 2 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

Jan 8, 2026, 4:05 PM EST - 3 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

Jan 7, 2026, 8:10 AM EST - 3 months ago

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

Dec 24, 2025, 1:05 PM EST - 4 months ago

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

Nov 13, 2025, 4:05 PM EST - 5 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

ImmuCell Announces Onboarding of New CEO and Related Management Changes

Nov 4, 2025, 4:05 PM EST - 6 months ago

ImmuCell Announces Onboarding of New CEO and Related Management Changes

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

Oct 7, 2025, 4:05 PM EDT - 7 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

ImmuCell Announces Selection of its Next President and CEO

Sep 29, 2025, 4:05 PM EDT - 7 months ago

ImmuCell Announces Selection of its Next President and CEO

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

Aug 14, 2025, 4:05 PM EDT - 9 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

ImmuCell Announces Bank Debt Refinancing

Aug 12, 2025, 4:05 PM EDT - 9 months ago

ImmuCell Announces Bank Debt Refinancing

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025

Aug 7, 2025, 8:00 AM EDT - 9 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

Jul 9, 2025, 8:00 AM EDT - 10 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

ImmuCell Embarks on CEO Succession Planning Process

Jun 25, 2025, 8:00 AM EDT - 10 months ago

ImmuCell Embarks on CEO Succession Planning Process

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

Jun 5, 2025, 6:30 AM EDT - 11 months ago

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

May 12, 2025, 8:42 AM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Apr 2, 2025, 4:05 PM EDT - 1 year ago

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Feb 25, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Feb 20, 2025, 8:19 AM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

Jan 16, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

Jan 9, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

Oct 8, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

Jul 9, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

Jun 5, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

May 8, 2024, 1:00 PM EDT - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

Apr 9, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Feb 27, 2024, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Feb 16, 2024, 9:30 AM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

Jan 8, 2024, 4:05 PM EST - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

Nov 13, 2023, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Nov 7, 2023, 12:15 PM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

Oct 5, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

ImmuCell Announces Submission of CMC Technical Section to the FDA

Aug 29, 2023, 8:00 AM EDT - 2 years ago

ImmuCell Announces Submission of CMC Technical Section to the FDA

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

Aug 7, 2023, 12:00 PM EDT - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

Jul 11, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

ImmuCell Announces Change in Timing of Anticipated FDA Submission

Jun 28, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Announces Change in Timing of Anticipated FDA Submission

ImmuCell Appoints Bryan K. Gathagan to Board of Directors

Jun 21, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Appoints Bryan K. Gathagan to Board of Directors

ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility

Jun 15, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility

theRooster007
theRooster007 Apr. 22 at 4:49 PM
$ICCC https://www.zacks.com/stock/news/2905060/the-zacks-analyst-blog-the-goldman-sachs-nextera-shopify-landmark-and-immucell
0 · Reply
theRooster007
theRooster007 Apr. 20 at 9:47 PM
$ICCC both on newest ceo and newest board member of the strategy and tech committee dr. Gilles guilmette resumes.....🤔
0 · Reply
theRooster007
theRooster007 Apr. 20 at 1:56 PM
$ICCC blue skies at $11
1 · Reply
theRooster007
theRooster007 Apr. 16 at 3:24 PM
$ICCC pe firm archimeds largest global animal health company Ceva can do manufacturing. Current ceo and newest leader of strategy committee linked to archimed.
0 · Reply
TommyTwenty
TommyTwenty Apr. 16 at 2:42 AM
$ICCC
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 6:08 PM
$ICCC RSI: 75.00, MACD: 0.2625 Vol: 0.48, MA20: 6.62, MA50: 6.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
focafoca99
focafoca99 Apr. 14 at 7:37 PM
$ICCC disclosed a board refresh with three directors stepping off and two new directors joining effective April 15.
0 · Reply
TommyTwenty
TommyTwenty Apr. 14 at 6:04 PM
$ICCC 1 new executive that comes from the same private equity firm as the new ceo. 1 new executive with a history of animal health M&A. They’re reducing the board to 7 after just reporting 28% sales increase. 6 independent directors and the ceo. The pop today on volume feels like buyout speculation.
0 · Reply
focafoca99
focafoca99 Apr. 13 at 10:01 PM
$ICCC added Gilles Guillemette and Anthony DiMarco to the board, reduced the board to seven seats and created a new Strategy and Technology Committee.
0 · Reply
theRooster007
theRooster007 Apr. 13 at 8:52 PM
$ICCC https://www.stocktitan.net/news/ICCC/immu-cell-bolsters-its-innovation-strategy-with-appointments-of-dr-6ru4bnelyvav.html
1 · Reply
focafoca99
focafoca99 Apr. 8 at 10:20 PM
$ICCC reported preliminary first-quarter sales of $10.4 million, up 28.4%, driven mainly by stronger Tri-Shield demand.
0 · Reply
Glopolon
Glopolon Apr. 8 at 8:28 PM
$ICCC Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. Great quarter, not sure, but probably first over $10M revenue
0 · Reply
TommyTwenty
TommyTwenty Apr. 8 at 8:25 PM
$ICCC https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-731452f7ef2f.html
0 · Reply
theRooster007
theRooster007 Apr. 1 at 3:57 AM
$ICCC data is coming https://archive.fast-edgar.com/20260330/AEZZB22CZC22R2Z2222P2WZZN7LMZ6T86U82/
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 7 at 12:57 AM
$ICCC Current Stock Price: $6.57
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 7:02 PM
$ICCC tightening the ship? Net loss narrows as sales and margins move higher. 📈 2025 sales rose 4.3% year over year, and gross margin expanded sharply — helping shrink the company’s annual net loss even with asset write-downs and ongoing strategic shifts. See what’s driving the improvement 👉 https://www.zacks.com/stock/news/2880426/immucell-2025-net-loss-narrows-yy-as-sales-margins-improve?cid=sm-stocktwits-2-2880426-teaser-36434&ADID=SYND_STOCKTWITS_TWEET_2_2880426_TEASER_36434
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 6:02 PM
$ICCC's 2025: Operational wins, but what's next? 📈 Product sales up 4.3% in 2025 compared to 2024, with net loss narrowing significantly. 🔧 Gross margin jumps to 41.4% from 30% due to improved production and manufacturing efficiencies. 📉 Q4 sales dip 1.6%, but domestic sales shine with an 8.7% increase. See what strategic shifts mean for ICCC's future 👉 https://www.zacks.com/stock/news/2880426/immucell-2025-net-loss-narrows-yy-as-sales-margins-improve?cid=sm-stocktwits-2-2880426-body-36435&ADID=SYND_STOCKTWITS_TWEET_2_2880426_BODY_36435
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 12:00 PM
$ICCC Q4 '25 Earnings Results & Recap Immucell reported 2025 product sales increased 4.3% to $27.6M, with gross profit improving to 41.4% from 30%. Net operating income reached $1.6M, an increase of $3.3M.
0 · Reply
theRooster007
theRooster007 Feb. 28 at 5:31 AM
$ICCC Data is coming 🥛 https://cvm.msu.edu/news/2026/pamela-ruegg-wins-national-mastitis-council-award-of-excellence
1 · Reply
SuperGreenToday
SuperGreenToday Feb. 27 at 1:17 AM
$ICCC
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 12:19 PM
$ICCC RSI: 58.00, MACD: 0.0803 Vol: 0.24, MA20: 6.32, MA50: 6.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LiquidityRisk
LiquidityRisk Feb. 20 at 1:24 PM
$ICCC ImmuCell focuses on animal health biologics. Revenue depends on agricultural demand. Margins are stable.
0 · Reply